The Colorectal Tumor drugs in development market research report provides comprehensive information on the therapeutics under development for Colorectal Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Colorectal Tumor. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Colorectal Tumor and features dormant and discontinued products.
GlobalData tracks five drugs in development for Colorectal Tumor by five companies/universities/institutes. The top development phase for Colorectal Tumor is preclinical with four drugs in that stage. The Colorectal Tumor pipeline has five drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Colorectal Tumor pipeline products market are: Abpro, Gilead Sciences and Oncovalent Therapeutics.
The key targets in the Colorectal Tumor pipeline products market include Small Ubiquitin Related Modifier Protein, Serine/Threonine Protein Kinase mTOR (FK506 Binding Protein 12 Rapamycin Complex Associated Protein 1 or FKBP12 Rapamycin Complex Associated Protein or Mammalian Target Of Rapamycin or Mechanistic Target Of Rapamycin or Rapamycin And FKBP12 Target 1 or Rapamycin Target Protein 1 or MTOR or EC 2.7.11.1), and Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2 (Metastatic Lymph Node Gene 19 Protein or Proto Oncogene Neu or Proto Oncogene C ErbB 2 or Tyrosine Kinase Type Cell Surface Receptor HER2 or p185erbB2 or HER2 or CD340 or ERBB2 or EC 2.7.10.1).
The key mechanisms of action in the Colorectal Tumor pipeline product include Serine/Threonine Protein Kinase mTOR (FK506 Binding Protein 12 Rapamycin Complex Associated Protein 1 or FKBP12 Rapamycin Complex Associated Protein or Mammalian Target Of Rapamycin or Mechanistic Target Of Rapamycin or Rapamycin And FKBP12 Target 1 or Ra with one drug in Phase II. The Colorectal Tumor pipeline products include three routes of administration with the top ROA being Intravenous and two key molecule types in the Colorectal Tumor pipeline products market including Small Molecule, and Monoclonal Antibody.
Colorectal Tumor overview
Colorectal cancer, or colon cancer, is a disease where cells in the colon or rectum grow out of control. Most colorectal cancers start as polyps, which are growths on the inner lining of the colon or rectum. Risk factors for colorectal cancer include increased age. Symptoms include change in bowel habits, rectal bleeding or blood in the stool, abdominal discomfort, weakness, and weight loss. Tests used for colon cancer diagnosis include colonoscopy, biopsy, and blood tests. Surgery, chemotherapy, bevacizumab, radiofrequency ablation, cryosurgery, radiation therapy, targeted therapy, ablation, and embolization are the treatment options available.
For a complete picture of Colorectal Tumor’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
